Beonic Ltd (BEO) ORDINARY FULLY PAID |
Information Technology |
$13 |
Application for quotation of securities - BEO
|
29 Aug 2024 9:37AM |
$0.023 |
$0.180 |
risen by
682.61%
|
|
Atomo Diagnostics Limited (AT1) ORDINARY FULLY PAID |
Health Care |
$12 |
FY24 Results Presentation
|
29 Aug 2024 9:37AM |
$0.021 |
$0.018 |
fallen by
14.29%
|
|
Butn Limited (BTN) ORDINARY FULLY PAID |
Financials |
$35 |
Appendix 4G
|
29 Aug 2024 9:36AM |
$0.069 |
$0.125 |
risen by
81.16%
|
|
Orcoda Limited (ODA) ORDINARY FULLY PAID |
Information Technology |
$14 |
Appendix 4G (Corporate Governance Statement disclosures)
|
29 Aug 2024 9:35AM |
$0.170 |
$0.075 |
fallen by
55.88%
|
|
Venture Minerals Limited (VMS) ORDINARY FULLY PAID |
Materials |
- |
Application for quotation of securities - VMS
|
29 Aug 2024 9:35AM |
$0.016 |
$0.012 |
fallen by
25%
|
|
Amcor Plc (AMC) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$9,784 |
Form 4s
|
29 Aug 2024 9:35AM |
$16.530 |
$15.160 |
fallen by
8.29%
|
|
Cromwell Property Group (CMW) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$969 |
FY24 Results Presentation
|
29 Aug 2024 9:35AM |
$0.415 |
$0.370 |
fallen by
10.84%
|
|
Spacetalk Ltd (SPA) ORDINARY FULLY PAID |
Information Technology |
$15 |
Response to ASX Price Query
|
29 Aug 2024 9:35AM |
$0.037 |
$0.210 |
risen by
467.57%
|
|
SPA - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant price change of SPA securities from $0.026 to $0.037.
- SPA is not aware of any unannounced information explaining recent trading.
- SPA confirms compliance with Listing Rule 3.1.
- SPA's responses have been authorized under its continuous disclosure policy.
- ASX requested information regarding unexplained trading volumes.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$186 |
FY24 Results Investor Presentation
|
29 Aug 2024 9:34AM |
$0.205 |
$0.300 |
risen by
46.34%
|
|
BBT - Price-sensitive ASX Announcement
Full Release
Key Points
- Transformational merger of BlueBet and betr completed.
- Strategic exit from the US to focus on the Australian market.
- Successful rebranding and customer migration to the betr brand.
- Realization of significant operating efficiencies and synergies.
- Record quarterly metrics show continued momentum in Australian trading.
- Group turnover up 18% compared to the previous corresponding period (pcp).
- Achieved the majority of technology-related synergies ahead of budget.
- Positive Australian trading momentum with first EBITDA positive year.
- Improved financial performance with a strong focus on customer retention and engagement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Prospect Resources Limited (PSC) ORDINARY FULLY PAID |
Materials |
$98 |
Share Purchase Plan Closing 4 September 2024
|
29 Aug 2024 9:34AM |
$0.100 |
$0.145 |
risen by
45%
|
|
Resimac Group Limited (RMC) ORDINARY FULLY PAID |
Financials |
$333 |
Resimac announces FY24 normalised NPAT of $43.1 million
|
29 Aug 2024 9:34AM |
$0.915 |
$0.840 |
fallen by
8.20%
|
|
RMC - Price-sensitive ASX Announcement
Full Release
Key Points
- Normalised NPAT of $43.1 million down 42% on FY23
- Statutory NPAT of $34.8 million down 47% on FY23
- Originations of $5.1 billion, up 21% on FY23
- AUM increased 2% to $14.0 billion
- Home loans decreased $0.2 billion to $12.9 billion
- Asset Finance increased $0.5 billion to $1.1 billion, up 76% on FY23
- NIM decreased 12 bps to 1.56% for FY24
- Opex down 3.3% or $2.8m versus FY23
- Fully franked dividend of 3.5 cents per share for 2H24, 7.0 cents for the full year
- Continued progress on diversification into asset finance
- Stability in Home Loans portfolio and significant growth in Asset Finance
- Increased broker applications and home loan settlements
- Recovery in Assets Under Management in the latter half of FY24
- Improved pricing on Residential Mortgage-Backed Securities deals
- Strong balance sheet and stable funding platform going into FY25
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$186 |
BlueBet FY24 results
|
29 Aug 2024 9:34AM |
$0.205 |
$0.300 |
risen by
46.34%
|
|
BBT - Price-sensitive ASX Announcement
Full Release
Key Points
- Transformational merger with betr completed on 1 July 2024
- Record turnover and net win in core Australian business for FY24
- Improved financial performance with first positive normalised EBITDA since IPO
- Exit from the US market to focus on Australian operations
- Expectation to reach monthly EBITDA profitability in H1 FY25
- Synergies from the merger with betr to drive profitability
- Rebrand and customer migration completed in 59 days
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Carnaby Resources Limited (CNB) ORDINARY FULLY PAID |
Materials |
$64 |
Drilling Update - Mohawk Discovery Drill Holes
|
29 Aug 2024 9:34AM |
$0.390 |
$0.280 |
fallen by
28.21%
|
|
CNB - Price-sensitive ASX Announcement
Full Release
Key Points
- Carnaby Resources Limited (ASX: CNB) announced the first drilling results from the Mohawk Prospect, part of the Greater Duchess Copper Gold Project.
- The initial two drill holes at Mohawk intersected significant copper sulphide mineralisation over wide intervals.
- pXRF readings from the drill holes MKRC001 and MKRC008 recorded notable copper intervals, including 21m @ 1.3% Cu from 43m in MKRC001 and 26m @ 0.8% Cu from 96m in MKRC008.
- Costean assay results also showed a strong gold association with copper mineralisation, including 10m @ 1.6% Cu, 0.4g/t Au.
- A major undrilled FLTEM modelled conductor plate is likely associated with copper sulphide mineralisation and is set for upcoming drilling.
- The Mohawk discovery has significant regional implications, with further exploration planned along the >2km long Mohawk corridor.
- Additional drilling at the Lady Fanny and Wimberu prospects yielded noteworthy copper and gold intersections.
- A large airborne VTEM survey is scheduled to commence in mid-September targeting the Mohawk corridor and additional areas.
- Carnaby Resources is advancing pre-feasibility studies and investigating future development options for the Greater Duchess Project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Resimac Group Limited (RMC) ORDINARY FULLY PAID |
Financials |
$333 |
Appendix 4E
|
29 Aug 2024 9:34AM |
$0.915 |
$0.840 |
fallen by
8.20%
|
|
RMC - Price-sensitive ASX Announcement
Full Release
Key Points
- FY24 revenue from ordinary activities increased by 11% to $1,006,677,000.
- Profit from ordinary activities after tax attributable to members decreased by 48% to $34,590,000.
- Net comprehensive income for the year attributable to members decreased by 57% to $31,466,000.
- Final FY24 dividend declared is 3.50 cents per share, fully franked.
- Interim FY24 dividend paid was 3.50 cents per share, fully franked.
- Net tangible assets per share increased to $1.15 from $0.93 in FY23.
- Earnings per share for FY24 were 8.65 cents basic and 8.64 cents diluted, compared to 16.52 cents basic and 16.48 cents diluted in FY23.
- The company's net assets stood at $416,361,000 as of 30 June 2024.
- The Group revised its accounting treatment of trail commission payable to mortgage brokers.
- The Board declared a fully-franked final dividend of 3.5 cents per share, with a record date of 6 September 2024, payable on 20 September 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Way 2 Vat Ltd (W2V) ORDINARY FULLY PAID |
Information Technology |
$6 |
Application for quotation of securities - W2V
|
29 Aug 2024 9:33AM |
$0.012 |
$0.006 |
fallen by
50%
|
|
BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$186 |
Appendix 4G and Corporate Governance Statement
|
29 Aug 2024 9:33AM |
$0.205 |
$0.300 |
risen by
46.34%
|
|
Way 2 Vat Ltd (W2V) ORDINARY FULLY PAID |
Information Technology |
$6 |
Application for quotation of securities - W2V
|
29 Aug 2024 9:33AM |
$0.012 |
$0.006 |
fallen by
50%
|
|
AVITA Medical, Inc. (AVH) CHESS DEPOSITARY INTERESTS 5:1 |
Health Care |
$214 |
Notification regarding unquoted securities - AVH
|
29 Aug 2024 9:33AM |
$2.660 |
$3.120 |
risen by
17.29%
|
|
Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$566 |
Corporate Governance Statement
|
29 Aug 2024 9:33AM |
$13.900 |
$11.290 |
fallen by
18.78%
|
|
Omni Bridgeway Limited (OBL) ORDINARY FULLY PAID US PROHIBITED |
Financials |
$436 |
FY24 Corporate Governance Statement and Appendix 4G
|
29 Aug 2024 9:33AM |
$0.840 |
$1.510 |
risen by
79.76%
|
|
Perpetual Limited (PPT) ORDINARY FULLY PAID |
Financials |
$1,869 |
ASX Release - Correction Letter
|
29 Aug 2024 9:33AM |
$20.640 |
$16.310 |
fallen by
20.98%
|
|
PPT - Price-sensitive ASX Announcement
Full Release
Key Points
- Perpetual Limited reported an underlying profit after tax (UPAT) for FY24 of A$206.1 million, up 26% on FY23.
- The total Assets Under Management (AUM) increased to A$215 billion.
- A final dividend of A$0.53 per share, 50% franked, was declared.
- Estimated cash proceeds for shareholders from the Scheme with KKR range between A$8.38 - A$9.82 per share.
- A simplification program aims to deliver annualised cost reductions of between A$25 million and A$35 million before tax, over two years.
- Orderly Board changes announced in anticipation of the completion of the transaction with KKR.
- Appointment of Bernard Reilly as CEO and Managing Director, succeeding Rob Adams.
- Perpetual's Wealth Management and Corporate Trust segments showed growth with respective UPBT increases of 15% and 4%.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$186 |
Appendix 4E and FY24 Annual Report
|
29 Aug 2024 9:33AM |
$0.205 |
$0.300 |
risen by
46.34%
|
|
BBT - Price-sensitive ASX Announcement
Full Release
Key Points
- BlueBet Holdings Ltd completed a transformational merger with betr, creating a leading Australian wagering operator.
- The company has exited the US market to focus on expanding its core Australian operations.
- Revenue increased by 19.8% to $59.5 million for the year ended 30 June 2024.
- The company reported a loss of $46.9 million, up 149.1% from the previous year.
- No dividends were paid or declared during the financial year.
- The merger with betr is expected to deliver $14 million in annualized cost savings.
- Active customers increased to 70,456, up 7.7% from the previous year.
- The company achieved its first full-year EBITDA positive result since IPO with an EBITDA of $3.3 million for its Australian operations.
- The company has implemented new compliance measures, including banning credit cards and integrating the National Self Exclusion Register.
- The strategic focus is now on growing market share in the Australian market and leveraging technology and product enhancements.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$566 |
Appendix 4G
|
29 Aug 2024 9:32AM |
$13.900 |
$11.290 |
fallen by
18.78%
|
|
Duxton Farms Ltd (DBF) ORDINARY FULLY PAID |
Consumer Staple |
$54 |
Update - Notification of buy-back - DBF
|
29 Aug 2024 9:32AM |
$1.595 |
$1.300 |
fallen by
18.50%
|
|
Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$566 |
Investor Presentation
|
29 Aug 2024 9:32AM |
$13.900 |
$11.290 |
fallen by
18.78%
|
|
CUV - Price-sensitive ASX Announcement
Full Release
Key Points
- CLINUVEL Pharmaceuticals Limited is focused on melanocortin-based pharmaceuticals for skin and brain conditions.
- The clinical pipeline includes treatments for various conditions such as xeroderma pigmentosum (XP), infantile spasms (IS), multiple sclerosis (MS), and central nervous system (CNS) disorders.
- SCENESSE® (afamelanotide 16 mg) is used in the treatment of erythropoietic protoporphyria (EPP) and is being trialed for other conditions like variegate porphyria, adolescent and adult XP, and vitiligo.
- NEURACTHEL® is being developed for instant and modified release forms to treat IS, MS, and CNS disorders.
- The company aims to build a diversified pharmaceutical group with multiple products and conditions treated, focusing on research and development, in-house manufacturing, and disciplined capital deployment.
- Financial performance includes maintaining cash reserves and disciplined capital investments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.